Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 ...

Moleculin Biotech Inc. (NASDAQ:MBRX) said it remains on track to unblind the first set of data from its pivotal Phase 2B/3 ...

Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...

Researchers at Carnegie Mellon University's School of Computer Science (SCS) revealed how small design changes in online tutoring platforms can help students push through their mistakes and keep ...

Using the BLISS-LN phase 3 study of belimumab, investigators studied biomarker associations with kidney response in lupus nephritis.

Use of genotype-guided SSRI shows no symptom improvement at 3 months in people with depression but is linked to higher ...

Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include ...

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secon ...

Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...